Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The oral MS product has its own renal eligibility limit. Injectable cladribine evidence does not repair or override that limit.
Before applying: Confirm indication and formulation before using a cladribine renal source.
Also check: MAVENCLAD: oral multiple-sclerosis restriction is not injectable oncology dosing
Rxlist source
GlobalRPh RX List - MAVENCLAD
Product / population
MAVENCLAD oral cladribine for multiple sclerosis; not injectable cladribine.
Renal measure
Creatinine clearance (CrCl), mL/min; selected passage does not establish an estimating equation.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
No renal dosage adjustment is recommended at CrCl 60-89 mL/min. MAVENCLAD is not recommended below CrCl 60 mL/min. Dedicated renal studies are lacking; the source describes limited experience below that threshold. These instructions concern oral MAVENCLAD for multiple sclerosis, not injectable oncology cladribine, and do not establish a dialysis dose.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-08. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
formulation scope
MAVENCLAD: oral multiple-sclerosis restriction is not injectable oncology dosing
The oral MS product has its own renal eligibility limit. Injectable cladribine evidence does not repair or override that limit.
How to use this: Confirm indication and formulation before using a cladribine renal source.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - Mavenclad
Oral cladribine tablets for multiple sclerosis. Not intravenous cladribine oncology dosing.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Oral cladribine tablets for multiple sclerosis. Not intravenous cladribine oncology dosing.
Renal method: CrCl, mL/min. Source date: Revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No dosage adjustment is recommended for mild renal impairment with CrCl 60 to 89 mL/min. MAVENCLAD is not recommended when CrCl is below 60 mL/min. Dedicated studies in renal impairment were not performed; do not extrapolate this oral restriction into an intravenous cladribine regimen.
RDM33-rxlist-cladribine-mavenclad-tablets-C1 · Source locator: Use in specific populations: renal impairment.
GlobalRPh-hosted RX List · MAVENCLAD oral cladribine for multiple sclerosis; not injectable cladribine.
Renal method: Creatinine clearance (CrCl), mL/min; selected passage does not establish an estimating equation. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No renal dosage adjustment is recommended at CrCl 60-89 mL/min. MAVENCLAD is not recommended below CrCl 60 mL/min. Dedicated renal studies are lacking; the source describes limited experience below that threshold. These instructions concern oral MAVENCLAD for multiple sclerosis, not injectable oncology cladribine, and do not establish a dialysis dose.
Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.